> Skip to content
FEATURED:
  • Philanthropy 50
  • Nonprofits and the Trump Agenda
  • Impact Stories Hub
Sign In
  • Latest
  • Commons
  • Advice
  • Opinion
  • Webinars
  • Online Events
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Career Advice
    • Find a Job
    • Post a Job
    • Career Advice
Sign In
  • Latest
  • Commons
  • Advice
  • Opinion
  • Webinars
  • Online Events
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Career Advice
    • Find a Job
    • Post a Job
    • Career Advice
  • Latest
  • Commons
  • Advice
  • Opinion
  • Webinars
  • Online Events
  • Data
  • Grants
  • Magazine
  • Store
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
    • Featured Products
    • Data
    • Reports
    • Collections
    • Back Issues
    • Webinars
  • Jobs
    • Find a Job
    • Post a Job
    • Career Advice
    • Find a Job
    • Post a Job
    • Career Advice
Sign In
ADVERTISEMENT
Individual Giving
  • Twitter
  • LinkedIn
  • Show more sharing options
Share
  • Twitter
  • LinkedIn
  • Email
  • Facebook
  • Copy Link URLCopied!
  • Print

Tim Ferriss on Giving for Psychedelic Research: It’s Personal

By  Marc Gunther
April 30, 2019
The loss of loved ones to addiction and his own struggles with depression and anxiety drive author and investor Tim Ferriss’s giving.
Drew Kelly
The loss of loved ones to addiction and his own struggles with depression and anxiety drive author and investor Tim Ferriss’s giving.

For Tim Ferriss, the best-selling author, podcaster, and investor, the decision to devote his philanthropy to research into psychedelic drugs is built on a solid foundation of peer-reviewed science. “I’ve spent hundreds of hours interacting with researchers to get a better understanding of the science,” he says.

It’s also deeply personal. Ferriss’s best friend from childhood died of a fentanyl overdose. An aunt, after injuring her shoulder, became addicted to Percocet and alcohol and died last year. Recently, Ferriss decided to help fund research at John Hopkins to see if psilocybin-assisted therapy could treat opioid addiction.

We're sorry. Something went wrong.

We are unable to fully display the content of this page.

The most likely cause of this is a content blocker on your computer or network.

Please allow access to our site, and then refresh this page. You may then be asked to log in, create an account if you don't already have one, or subscribe.

If you continue to experience issues, please contact us at 571-540-8070 or cophelp@philanthropy.com

For Tim Ferriss, the best-selling author, podcaster, and investor, the decision to devote his philanthropy to research into psychedelic drugs is built on a solid foundation of peer-reviewed science. “I’ve spent hundreds of hours interacting with researchers to get a better understanding of the science,” he says.

It’s also deeply personal. Ferriss’s best friend from childhood died of a fentanyl overdose. An aunt, after injuring her shoulder, became addicted to Percocet and alcohol and died last year. Recently, Ferriss decided to help fund research at John Hopkins to see if psilocybin-assisted therapy could treat opioid addiction.

What’s more, Ferriss himself struggled with depression and anxiety as a college student at Princeton. He tried “magic mushrooms,” which contain psilocybin, and found relief. “I was able to finally see things clearly,” he says, “to appreciate all of the incredible chance blessings that I experienced in my life.”

Ferriss, who is now 42, is quick to caution that no one should experiment with illegal drugs under uncontrolled circumstances. But like many, if not most, of the donors to psychedelic science, his passion is driven both by the head and the heart. Usona founder Bill Linton, Cody Swift of the Riverstyx Foundation, and David Bronner, who leads Dr. Bronner’s, which makes organic personal-care products, have all experienced or seen up close the healing potential of psychedelics.

Donors are also motivated because, they say, conventional treatments for the pain caused by PTSD, depression, anxiety, and addiction often fall short.

ADVERTISEMENT

Drug overdoses killed more than 70,000 Americans in 2017, which is more than the number who died during the entire Vietnam War, Ferriss notes.

“These compounds are by no means a panacea,” Ferriss says. “But they show tremendous promise for serious conditions that currently have few or no effective treatments.”

Ferriss has formed a foundation and pledged $2 million of his own money to fund psychedelic science. “Having done a few years of due diligence,” he adds, “I’ve decided to push all my chips in.”

A version of this article appeared in the May 1, 2019, issue.
We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Fundraising from Individuals
Marc Gunther
Marc Gunther is a veteran reporter who writes about philanthropy, psychedelic medicines, and drug policy. His website is www.marcgunther.com.
ADVERTISEMENT
ADVERTISEMENT
SPONSORED, GEORGE MASON UNIVERSITY

Related Content

  • With Government Skittish About Psychedelics, Philanthropy Funds Promising Research
  • Explore
    • Latest Articles
    • Get Newsletters
    • Advice
    • Webinars
    • Data & Research
    • Podcasts
    • Magazine
    • Chronicle Store
    • Find a Job
    • Impact Stories
    Explore
    • Latest Articles
    • Get Newsletters
    • Advice
    • Webinars
    • Data & Research
    • Podcasts
    • Magazine
    • Chronicle Store
    • Find a Job
    • Impact Stories
  • The Chronicle
    • About Us
    • Our Mission and Values
    • Work at the Chronicle
    • User Agreement
    • Privacy Policy
    • California Privacy Policy
    • Gift-Acceptance Policy
    • Gifts and Grants Received
    • Site Map
    • DEI Commitment Statement
    • Chronicle Fellowships
    • Pressroom
    The Chronicle
    • About Us
    • Our Mission and Values
    • Work at the Chronicle
    • User Agreement
    • Privacy Policy
    • California Privacy Policy
    • Gift-Acceptance Policy
    • Gifts and Grants Received
    • Site Map
    • DEI Commitment Statement
    • Chronicle Fellowships
    • Pressroom
  • Customer Assistance
    • Contact Us
    • Advertise With Us
    • Post a Job
    • Reprints & Permissions
    • Do Not Sell My Personal Information
    • Advertising Terms and Conditions
    Customer Assistance
    • Contact Us
    • Advertise With Us
    • Post a Job
    • Reprints & Permissions
    • Do Not Sell My Personal Information
    • Advertising Terms and Conditions
  • Subscribe
    • Individual Subscriptions
    • Site License Subscriptions
    • Subscription & Account FAQ
    • Manage Newsletters
    • Manage Your Account
    Subscribe
    • Individual Subscriptions
    • Site License Subscriptions
    • Subscription & Account FAQ
    • Manage Newsletters
    • Manage Your Account
1255 23rd Street, N.W. Washington, D.C. 20037
© 2025 The Chronicle of Philanthropy
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin